Specifically, in patients diagnosed with lymph node metastases, the relative mean expression of FEZF1-AS1 was over 2.30 fold higher than in patients without metastases, indicating that FEZF1-AS1 might have a fundamental role in CRC metastasis. Here, FEZF1 is linked to metastatic malignant neoplasm in the lymph nodes.